Diasome Presents Phase 2b Data Demonstrating HDV™-Insulin Lispro Maintains Glycemic Control While Reducing Hypoglycemia in Adults with Type 1 Diabetes

The OPTI-2 trial provides early clinical evidence that liver-targeted mealtime insulin may help decouple tight glucose control from hypoglycemia risk, a longstanding tradeoff in intensive insulin therapy that has persisted despite advances in monitoring and delivery technologies Diasome Pharmaceuticals' Hepatocyte-Directed Vesicle (HDV™) Technology Three-dimensional rendering of a hepatocyte-directed vesicle (HDV), the delivery platform underlying HDV-insulin lispro. The disc-shaped phospholipid